Bosentan and Sitaxsentan

Endothelin receptor antagonists

Randomized controlled trials of oral endothelin receptor antagonists

Trial Channick et al. 2001 Rubin et al. 2002 Barst et al. 2002
Prostanoid Bosentan Bosentan Sitaxsentan
Patients (n) 32 213 178

Etiology of PH
IPAH / CTD / CHD
CTEPH / HIV / PPHTN

85 / 15 / 0
 0 / 0 / 0
70 / 30 / 21
 0 / 0 / 0
53 / 24 / 24
 0 / 0 / 0
NYHA II / II / IV (%) 0 / 100 / 0 91 / 9 / 0 33 / 66 / 1
Duration (m) 3 4 3
Primary endpoint 6-MW
+ NYHA
6-MW Peak VO2
Improvement in 6-MW (m) compared to controls +76 +44 +34
Improvement in other endpoints Hemodyn,
NYHA
Clinical events
NYHA
Clinical events
 
Side effects (n) Elevated
transaminases
Elevated
transaminases
Elevated
transaminases